当前位置:首页 > 报告详情

Clarivate:2024年暂未引发关注的ADC创新公司报告(56页).pdf

上传人: 海*** 编号:177961 2024-10-16 56页 7.37MB

下载:

1、ADC202427ADC040607ADC102023ADC16ADC19ADC2324 Adcendo ApS28 Araris Biotech AG32 GO Therapeutics36 Heidelberg Pharma AG41 Pheon Therapeutics45 Tallac Therapeutics,Inc49 Tubulis 53ADC IPADCBioWorldCortellisCortellisCortellisCortellisOFF-X4AIDTSR5Matthew Arnold Shilpa Bali Yanbing Bertho John Borgman So

2、nia Giral Lopez Padma Sekhar Mike Ward Angela Weidner(ADC)ADCADC(Pzer Inc)430Seagen Inc(AbbVie)100ImmunoGen(Johnson&Johnson)20Ambrx Biopharma Inc(mAb)ADCmAbADCADCADCADCADC(CDMO)ADCADCADC6ADC601202403ADC10ADC(MoA)ADCADCADCADCADCADCADCADCADCADCADC7ADC(RWE HEOR)ADCADCADCADCADC(IP)ADC8ADCADC5ADC92023ADC

3、ADC15331020231220ADCifinatamab deruxtecanpatritumab deruxtecanraludotatugderuxtecan420227ADC2022515ADC12010080604020040353025201550Cortellis102020202120222023201910152019-202310patritumabderuxtecan(HER3 DXd)inifituzumabderuxtecan(I DXd)raludotatugderuxtecan(R DXd)22 02023 10 197ADC9 52022 12 22DXdAD

4、CDS 8201(trastuzumabderuxteca)(NSCLC)6 92019 03 28DS 1062(datopotamabderuxtecanNSCLC(TNBC)6 02020 07 27GenmabA SGenmabepcoritamab(DuoBody CD3xCD20)DuoHexaBody CD37DuoBody CD3x5T43 92020 06 10NurixTherapeuticsIncSeagenIncNurixTherapeuticsDELigase(DAC)3 52023 09 07SeagenInc(SeattleGenetics)ladiratuzum

5、abvedotin3 22020 09 14MORAb 2023 12021 06 17RemeGenCoLtdSeagenIncdisitamabvedotin(RC 48)2 62021 08 09BB 17012 02023 05 08Synafix B VSynaffixADCSynaffixB V42 02023 01 05Cortellis112024412202432ADC5 Systimmune84BL B01D1NSCLC2024417 Caris Discovery14ADC 202444 MediLink Therapeutics10MediLink Therapeuti

6、csYL 211202412 Sutro Biopharma IncIpsen8 99STRO 003202442515ADC2023750%430Seagen22420221215(COVID 9)Seagen(PfizerInc)114FDAADCETRISPADCEVenfortumabvedotin TIVDAKtisotumabvedotinADCTUKYSAtucatinibTKI2030100202441220243ADC ImmunoGen1012024212 Ambrx Biopharma Inc20202437 Genmab A S18202443252019-2023AD

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了抗体药物偶联物(ADC)的研究进展和市场动态。 key points:1. 目前有多个ADC药物正在进行临床试验,其中一些已经获得了FDA的批准,如Mylotarg和Trop2乳腺癌药物。2. 2023年,Merck与Daiichi Sankyo达成了一项价值高达22亿美元的ADC合作协议,创下记录。3. 2023年,Pfizer宣布将以43亿美元收购Seagen,进一步推动ADC市场的发展。4. EMA validate two filings for Daiichi Astrazeneca's ADC, indicating the company's commitment to this field.5. There are many other ADC drugs in development, with a focus on targeting specific cancer markers, such as CD33 and BCMA.6. The ADC market is expected to continue growing, with more approvals and launches in the near future.
"ADC技术在癌症治疗中的最新进展有哪些?" "如何评价Pfizer收购Seagen的影响?" "Daiichi Sankyo的ADC药物Trop2在乳腺癌治疗中的潜力如何?"
客服
商务合作
小程序
服务号
折叠